# Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents

> **NCT03343444** · PHASE3 · UNKNOWN · sponsor: **Egyptian Liver Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Hepatitis C Virus Infection, Response to Therapy of

## Interventions

- **DRUG:** 12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)
- **DRUG:** 8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)

## Key facts

- **NCT ID:** NCT03343444
- **Lead sponsor:** Egyptian Liver Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-15
- **Primary completion:** 2018-11-01
- **Final completion:** 2019-05-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2018-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03343444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03343444, "Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03343444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*